Health Care/Hospital
Rising Through Challenge: Living Phoenix's 2026 New Year Message POGMENT Biomimetic Collagen
CHENGDU, China, Jan. 1, 2026 /PRNewswire/ -- As the Year of the Horse begins, bringing new momentum and promise,Living Phoenix—a pioneer in next-generation biomaterials—wishes all friends, partners, and users a joyful New Year. May you stay young, steady, and ready to gallop forward into 2026. ...
2026-01-01 12:36
1274
POGMENT Biomimic Collagen Reacquired Recognition, Founder Appointed as Industrial Mentor for Master's Students at East China Normal University, Awarded 2025 Innovation Leadership Award
CHENGDU, China, Dec. 31, 2025 /PRNewswire/ -- On December 27, the 2025 Master of Engineering Management (MEM) Industry Mentor Orientation and Appointment Ceremony was held at the Wenshi Building on the Putuo Campus of East China Normal University (ECNU), located at No. 3663 Zhongshan North Road, ...
2025-12-31 17:21
3735
Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula
BANGKOK, Dec. 31, 2025 /PRNewswire/ -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach to gut health, ...
2025-12-31 15:46
3265
KLMBio Accelerates Global Expansion in Bone Graft Market with Human Tissue-Based Medical Devices
SEOUL, South Korea, Dec. 31, 2025 /PRNewswire/ -- KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value tissue-based product portfolio to target the rapidly growing global bone graft market. The gl...
2025-12-31 12:44
1508
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange
SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on theHong Kong stock m...
2025-12-31 08:55
1807
Entering the New Year, VARON Strengthens Commitment to Dependable Oxygen Support
NEW YORK, Dec. 30, 2025 /PRNewswire/ -- As the new year begins, it offers a
meaningful moment to reflect on shared progress and renewed responsibility in
respiratory care. Over the past year, VARON
2025-12-31 07:34
1266
Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring
SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scar...
2025-12-30 22:00
1720
China's Sleep Technology Pioneer Sleemon Draws Increasing Interest from the Global AI Community
SHAOXING, China, Dec. 30, 2025 /PRNewswire/ -- A long-established household brand inChina with a comparatively limited international profile, Sleemon Healthy Sleep Technology Co., Ltd. is gaining attention from the global technology community as it expands its focus on advanced sleep technology ...
2025-12-30 21:54
1457
The "Eastern Wisdom" of Aging: How Taikang's "New Life Insurance" Responds to a Global Challenge?
SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Under the global background of ageing people, WallstreetCN reported how TaiKang play its wisdom in new-life-insurance. In 2014, journalists from Japan's NHK documented the phenomenon of A Society Without Bonds, portraying how the elderly in an atomized soci...
2025-12-30 19:34
1658
Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO
HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public ...
2025-12-30 17:00
3190
Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards
SHENZHEN, China, Dec. 29, 2025 /PRNewswire/ -- On December 5, 2025, Dr. Lu
Xianping, Founder, Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, has
been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025
awards.
2025-12-30 08:45
2130
Bioelectric Toothbrush Offers New Approach with 6x Plaque Removal
Clinically validated microcurrent technology now available in the U.S. market SAN FRANCISCO, Dec. 29, 2025 /PRNewswire/ -- Great Gums Inc. today announced the U.S. launch of its bioelectric toothbrush, a clinically validated oral care device that delivers safe microcurrents to remove plaque from ...
2025-12-29 21:00
2045
HKSH Medical Group and Southern University of Science and Technology Collaborate for Medical and Medical Physics Training, Enhancing Medical Education and Research Innovation
HONG KONG, Dec. 29, 2025 /PRNewswire/ -- HKSH Medical Group ("HKSH") and Southern University of Science and Technology ("SUSTech") officially signed a Memorandum of Understanding ("MOU") on15 December 2025, a significant initiative to deepen collaboration betweenHong Kong and the Chinese Mainland...
2025-12-29 16:12
2135
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology pl...
2025-12-29 14:13
1829
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE
SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immu...
2025-12-29 13:52
2445
Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
TAIPEI and SAN DIEGO, Dec. 28, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. ...
2025-12-29 10:24
1767
Assure Healthcare Holdings Opens Second Clinic in Woodlands, Singapore
SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic,Assure Family Clinic Woodlands. This expansion marks the next phase in the Group's mission to make quality and comprehensive healthca...
2025-12-29 10:00
1256
Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a l...
2025-12-29 09:58
1375
Festive Season Isolation: How Eczema Is Keeping Singaporeans From Gatherings
Medical Channel Asia's ongoing eczema survey reveals how chronic itch drives withdrawal, emotional strain, and missed celebrations during a period traditionally associated with connection and joy. SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- For many, the festive season is marked by reunions, shared...
2025-12-29 08:30
1157
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596
SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administr...
2025-12-29 08:10
1061
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 269 media titles]
2026-01-01 10:00
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00